Draft:Braini - Clinically Tested Brain Supplement

• Comment: In accordance with Wikipedia's Conflict of interest policy, I disclose that I have a conflict of interest regarding the subject of this article. Twgsb (talk) 16:35, 30 May 2025 (UTC)

---

1. Save the full text of the Wikipedia submission version as a downloadable .txt file

wikipedia_submission_path = "/mnt/data/BRAINI_Wikipedia_Submission.txt" with open(wikipedia_submission_path, "w") as file:

   file.write("""

BRAINI

BRAINI is a trademarked cognitive health supplement developed in the United States and launched in 2017 by entrepreneur Troylyn Ball. The product is designed to support executive function, attention, memory, and overall cognitive performance. The formulation was developed in collaboration with researchers and ingredient manufacturers in South Korea, Canada, and North America.

BRAINI is marketed as a stimulant-free alternative to traditional nootropics. The intellectual property for the formulation is held by Brain Health Holding Company, and the exclusive product license for supplements is managed by BRAINI LLC.

The BRAINI formulation was created following an extensive worldwide search for natural ingredients that had been clinically proven to support brain function. The management team at BRAINI prioritized using only ingredients backed by double-blinded, peer-reviewed, and published clinical research. All three of BRAINI's active ingredients have independently demonstrated cognitive benefits in human trials.

Ingredients and Formulation

BRAINI contains a proprietary blend of three natural active ingredients:

Peptylin (Silk Peptide, BF-7)

Peptylin is the branded name for a silk-derived peptide previously studied under the name BF-7 and is exclusively produced by Famenity Co., Ltd. in South Korea. Derived from Bombyx mori cocoons using enzymatic hydrolysis, it has demonstrated neuroprotective and cognitive-enhancing effects in multiple human and animal studies.

• Kim K, et al. (2009). Brain Factor-7 Extracted from Bombyx mori Enhances Cognition and Attention in Children. Journal of Medicinal Food.
• Noh Y, et al. (2020). BF-7 improves learning and memory deficits and reduces ROS in stroke in vivo and in vitro.
• Lanou AJ, et al. (2023). BRAINI Clinical Trial. Journal of Integrative and Complementary Medicine.

NeurXcel (Plant-Based Omega-3 SDA)

NeurXcel is a plant-based omega oil rich in stearidonic acid (SDA), a precursor to EPA. It is derived from the seeds of Buglossoides arvensis and produced by Nature’s Crops International.

• Strand EA, et al. (2013). SDA-rich supplement increases EPA levels.

Wild Canadian Blueberries

BRAINI uses wild-harvested blueberries from Canada, which are rich in anthocyanins and antioxidants.

• Krikorian R, et al. (2010). Blueberry supplementation improves memory.
• Miller MG, Shukitt-Hale B. (2012). Berry fruit enhances brain function.

Clinical Research

In 2023, a double-blinded, placebo-controlled clinical trial was conducted by researchers at the University of North Carolina at Asheville in collaboration with BRAINI LLC using the CNS Vital Signs testing platform.

• Lanou AJ, Mast AC, Hill BD, Kim SS, Hanaway P. A Randomized, Placebo-Controlled Clinical Trial of a Novel Dietary Supplement (BRAINI). Journal of Integrative and Complementary Medicine.

Special Findings in Dyslexia

The patented data supporting BRAINI includes results from six individuals with dyslexia who showed significant cognitive improvement on CNS Vital Signs tests in Morrisville, North Carolina. After 30 days of supplementation:

• Cognitive Flexibility improved by 95.76%
• Executive Function improved by 93.19%
• Reaction Time improved by 20.06%

Consumer Cognitive Testing

BRAINI partnered with CNS Vital Signs to allow customers to take a baseline neurocognitive test, supplement for 30 days, and receive a follow-up report comparing results.

Patents and Intellectual Property

BRAINI’s formulation is protected under three U.S. patents: one Composition of Matter patent and two Methods patents, assigned to Brain Health Holding Company and licensed to BRAINI LLC:

• U.S. Patent No. 11,313,176 B2
• U.S. Patent No. 11,707,497 B2
• U.S. Patent No. 11,357,810 B2

These patents cover treatment or support for:

• Alzheimer’s disease and dementia
• Memory loss, brain fog (including post-COVID and chemotherapy-related)
• ADD/ADHD, autism spectrum disorder, dyslexia
• Depression, anxiety, sleep disorders
• Multiple sclerosis, Parkinson’s disease
• Demyelination disorders, strabismus, concussion

Regulatory Status

BRAINI is stimulant-free and caffeine-free. It was submitted under New Dietary Ingredient Notification (NDIN 1143) to the U.S. FDA and determined safe for use across all age groups.

Company Information

• Trademarked logo: BRAINI is a registered trademark.
• Address: 2385 Hendersonville Road, Suite 1812, Arden, North Carolina, 28704
• Website: [1]
• CEO: Troylyn Ball
• President: Marcus Goddard, PhD

References

1. Kim K, et al. (2009). "Brain Factor-7 Extracted from Bombyx mori Enhances Cognition and Attention in Children." Journal of Medicinal Food. [2](https://pubmed.ncbi.nlm.nih.gov/19627215/) 2. Noh Y, et al. (2020). "BF-7 improves learning and memory deficits and reduces ROS in stroke in vivo and in vitro." [3](https://pubmed.ncbi.nlm.nih.gov/32760664/) 3. Lanou AJ, Mast AC, Hill BD, Kim SS, Hanaway P. (2023). "A Randomized, Placebo-Controlled Clinical Trial of a Novel Dietary Supplement (BRAINI)." Journal of Integrative and Complementary Medicine. [4](https://www.liebertpub.com/doi/10.1089/jicm.2022.0543) 4. Strand EA, et al. (2013). "SDA-rich supplement increases EPA levels." [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3738994/) 5. Krikorian R, et al. (2010). "Blueberry supplementation improves memory." [6](https://pubmed.ncbi.nlm.nih.gov/20047325/) 6. Miller MG, Shukitt-Hale B. (2012). "Berry fruit enhances brain function." [7](https://pubmed.ncbi.nlm.nih.gov/22301879/)

See Also

• Nootropic
• Cognitive enhancement
• Functional foods
• Clinical nutrition

""")

wikipedia_submission_path